drugset / Trial / NCT05624853

A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

NCT05624853

Phase 4 Completed 130 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to compare the efficacy and safety of pregabalin sustained release tablet and pregabalin immediate release capsule in type II diabetic patients with peripheral neuropathic pain.

Timeline

Start
2020-05-12
Primary completion
2022-12-20
Completion
2022-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg
Subject Pregabalin Small molecule 150 mg